GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Dr. Marc Hertz will deliver a presentation on September 9, 2025, at 3:00 PM ET in New York. Management will also conduct one-on-one meetings with qualified investors during the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days after the event.

Live webcast presentation with CEO, Dr. Marc Hertz, on September 9^th at 3:00 PM ET

LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at 3:00 PM ET on Tuesday, September 9, 2025 at the H.C. Wainwright 27^th Annual Global Investment Conference being held in New York, NY. 

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. 

A live webcast of the presentation will be available on the Events page under the Investors section of the Company’s website (gribio.com). The webcast replay will be archived for 90 days following the event.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com

FAQ

When is GRI Bio presenting at the H.C. Wainwright Conference?

GRI Bio's CEO Dr. Marc Hertz will present on Tuesday, September 9, 2025, at 3:00 PM ET at the conference in New York.

Where can I watch GRI Bio's H.C. Wainwright conference presentation?

The presentation will be available via live webcast on GRI Bio's website (gribio.com) under the Investors section's Events page, with the replay available for 90 days.

What is GRI Bio's main focus as a company?

GRI Bio is a biotechnology company developing Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.

Will GRI Bio management be available for meetings at the H.C. Wainwright conference?

Yes, management will be available for one-on-one meetings with qualified investors who are registered for the conference.